1-6 of 6
Aditi Shastri
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation

Available to Purchase
Ritesh K. Aggarwal, Simone Sidoli, Jingli Wang, Srabani Sahu, Rahul Sanawar, Varun Gupta, Srinivas Aluri, Vineeth Sukrithan, Charan T.R. Vegivinti, Phaedon D. Zavras, Divij Verma, Shanisha Gordon-Mitchell, Beamon Agarwal, Tanya Verma, Daniel T. Starczynowski, Ulrich G. Steidl, Aditi Shastri, Balazs Halmos, Lindsay M. LaFave, Haiying Cheng, Amit Verma, Yiyu Zou
Journal: Clinical Cancer Research
Clin Cancer Res (2025) 31 (4): 746–755.
https://doi.org/10.1158/1078-0432.CCR-24-2182
Published: 17 February 2025
View articletitled, Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation
Open the PDF for Smoking-Associated Carcinogen–Induced Inflammation Promotes Lung Carcinogenesis via IRAK4 Activation in another window
Includes: Supplementary data
Journal Articles

A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML

Available to Purchase
David Levitz, Yogen Saunthararajah, Kateryna Fedorov, Lauren C. Shapiro, Ioannis Mantzaris, Aditi Shastri, Noah Kornblum, R. Alejandro Sica, Nishi Shah, Marina Konopleva, Kira Gritsman, Ira Braunschweig, Dennis L. Cooper, Kith Pradhan, Amit Verma, Eric J. Feldman, Mendel Goldfinger
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (15): 2774–2780.
https://doi.org/10.1158/1078-0432.CCR-23-0842
Published: 01 August 2023
View articletitled, A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML
Open the PDF for A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML in another window
Includes: Supplementary data
Journal Articles

Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial

Available to Purchase
Jesus D. Gonzalez-Lugo, Suman Kambhampati, Abdulraheem Yacoub, William B. Donnellan, Jesus Berdeja, Prafulla Bhagat, Karen Fehn, Cassady Remy, Sakshi Jasra, Mohammed Kazemi, Kith Pradhan, Mimi Kim, Ioannis Mantzaris, R. Alejandro Sica, Nishi Shah, Mendel Goldfinger, Noah Kornblum, Kira Gritsman, Ira Braunschweig, Ulrich Steidl, Britta Will, Aditi Shastri, Amit Verma
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (1): 60–66.
https://doi.org/10.1158/1078-0432.CCR-22-1457
Published: 04 January 2023
View articletitled, Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial
Open the PDF for Lenalidomide and Eltrombopag for Treatment of Low- or Intermediate-Risk Myelodysplastic Syndrome: Result of a Phase II Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road

Available to Purchase
Diego A. Adrianzen-Herrera, Aditi Shastri
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (19): 4167–4170.
https://doi.org/10.1158/1078-0432.CCR-22-1881
Published: 03 October 2022
View articletitled, Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road
Open the PDF for Unrelated Allogeneic Stem Cell Transplant in Relapsed/Refractory AML: Widening the Yellow Brick Road in another window
Journal Articles

Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions

Open Access
Phaedon D. Zavras, Aditi Shastri, Mendel Goldfinger, Amit K. Verma, Yogen Saunthararajah
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6653–6661.
https://doi.org/10.1158/1078-0432.CCR-21-2139
Published: 15 December 2021
View articletitled, Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions
Open the PDF for Clinical Trials Assessing Hypomethylating Agents Combined with Other Therapies: Causes for Failure and Potential Solutions in another window
Journal Articles

Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer

Available to Purchase
Aditi Shastri, Diego A. Adrianzen-Herrera
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (22): 6069–6071.
https://doi.org/10.1158/1078-0432.CCR-21-2578
Published: 15 November 2021
View articletitled, Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer
Open the PDF for Ruxolitinib in CMML: A Case Study of Innovative Trial Design in a Rare Cancer in another window